First, there???s a need to show that these antibodies work in various types of bacteria, and the first successes, not only clinical successes, but also when you publish your data for how they work in different disease models, can really help the field grow and encourage others to use this augumentative approach.??? With sufficient arrays of mAbs and mAb cocktails, physicians will have a choice of